Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2015 - 2026)

Biocryst Pharmaceuticals has reported Amortizatization of Intangibles for 12 years, with the latest figure at $600000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortizatization of Intangibles rose 143.38% year-over-year to $600000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.3 million (up 75.73% YoY), and the FY2025 full-year result was -$4.3 million, up 62.25% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $600000.0, up from -$1.1 million in the prior quarter.
• The five-year high for Amortizatization of Intangibles was $600000.0 in Q1 2026, with the low at -$3.5 million in Q2 2024.
• Historically, Amortizatization of Intangibles has averaged -$1.6 million across 5 years, with a median of -$1.4 million in 2025.
• Annual changes were most pronounced in 2022 — Amortizatization of Intangibles sank 73100.0% — and 2026, when it surged 143.38%.
• Biocryst Pharmaceuticals' Amortizatization of Intangibles stood at -$959000.0 in 2022, then tumbled by 259.65% to -$3.4 million in 2023, then climbed by 19.98% to -$2.8 million in 2024, then surged by 60.47% to -$1.1 million in 2025, then soared by 155.0% to $600000.0 in 2026.
• The last three Amortizatization of Intangibles figures came in at $600000.0 (Q1 2026), -$1.1 million (Q4 2025), and -$707000.0 (Q3 2025), per Business Quant data.